Biliary Tract Neoplasms: Clinical Trials

854 trials for Biliary Tract Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

328 completed, 159 recruiting, 141 unknown, 69 terminated. 405 Phase 2, 191 Phase 1, 115 Not applicable, 73 Phase 3, 17 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2405Completed 140, Recruiting 73, Unknown 61, Terminated 38, Not yet recruiting 37, Active not recruiting 36, Withdrawn 15, Enrolling by invitation 4, Suspended 1
Phase 1191Completed 89, Recruiting 48, Terminated 17, Unknown 15, Active not recruiting 14, Not yet recruiting 4, Withdrawn 3, Suspended 1
Not applicable115Completed 43, Unknown 28, Recruiting 19, Not yet recruiting 8, Terminated 6, Active not recruiting 5, Withdrawn 3, Suspended 2, Enrolling by invitation 1
Phase 373Completed 24, Recruiting 14, Unknown 10, Active not recruiting 8, Terminated 8, Not yet recruiting 5, Withdrawn 3, Enrolling by invitation 1
Phase 417Completed 7, Unknown 4, Recruiting 3, Not yet recruiting 2, Withdrawn 1
Early Phase 11Recruiting 1

Follow Biliary Tract Neoplasms: new trials by email Literature Review of Biliary Tract Neoplasms trials Research Report on Biliary Tract Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
Envafolimab plus Gemcitabine&Cisplatin, Gemcitabine&Cisplatin - Biliary Tract Neoplasms
Phase 2Not yet recruiting3D Medicines (Sichuan) Co., Ltd.1262027-06-012026-03-25
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer
Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC)
Phase 3Not yet recruitingUNICANCER9902027-01-022026-08-04
TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)
Music-assisted relaxation and imagery (MARI) - Surgery, Stomach Cancer
Not applicableNot yet recruitingCase Comprehensive Cancer Center202027-01-012026-08-05
Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer
Daraxonrasib - Biliary Tract Cancer (BTC)
Phase 2Not yet recruitingNational Health Research Institutes, Taiwan552027-01-012026-11-02
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma
Phase 1Not yet recruitingAccSalus Biosciences, Inc.402027-01-012026-10-28
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
Actigraphy, Online Mindfulness Meditation, Smartphone Application-based Intervention - Hepatocellular Carcinoma, Pancreas Cancer
Not applicableNot yet recruitingCity of Hope Medical Center702027-01-012026-11-10
PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency Genes
Olaparib + durvalumab - Biliary Tract Cancer (BTC)
Phase 2Not yet recruitingInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest402027-01-012026-11-16
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
[225Ac]Ac-FL-261 - Solid Tumor, NSCLC
Phase 1 / Phase 2RecruitingFull-Life Technologies UK Limited2082026-12-012026-11-16
HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers
HLX22, Serplulimab, trastuzumab - Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis)
Phase 2Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology1282026-12-012026-11-16
Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors
Zanidatamab - Biliary Tract Cancer
Phase 2Not yet recruitingAnhui Provincial Hospital152026-11-302026-10-01
Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer
Oxaliplatin, 5-Fluorouracil, Capecitabine - Biliary Tract Cancer, Cholangiocarcinoma
Phase 3Not yet recruitingZhai Wenlong902026-11-302026-11-04
Tucatinib Continuation Study
tucatinib - HER2-positive Breast Cancer, Cervical Cancer
Phase 4Not yet recruitingPfizer1752026-11-062026-08-28
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma
Phase 2RecruitingOhio State University Comprehensive Cancer Center292026-11-012026-09-10
IKS04 Regimen in Advanced Solid Tumors That Express CA242
IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody - Colorectal Cancer, Gastro Esophageal Junctional Cancer
Phase 1Not yet recruitingIksuda Therapeutics Ltd.1202026-11-012026-07-31
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc)
Phase 2Not yet recruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins552026-11-012026-11-10
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ
Phase 1 / Phase 2RecruitingCrescent Biopharma, Inc.2192026-10-212026-11-02
Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node Metastases
Primary Tumor Resection and Selective Lymph Node Dissection, Postoperative Radiotherapy, Capecitabine or S-1 - Biliary Tract Cancer (BTC), Surgery
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences732026-10-082026-10-26
Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors
PD-1 and chemotherapy, cryoablation - Biliary Tract Cancer (BTC)
Phase 2RecruitingTianjin Medical University Cancer Institute and Hospital302026-10-012026-07-24
A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer
Ivonescimab, GEMOX Regimen - Biliary Tract Cancer (BTC)
Phase 2RecruitingHaitao Zhao, MD872026-10-012026-10-02
A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer
Sacituzumab Tirumotecan (SKB264), Pembrolizumab - Biliary Tract Cancer (BTC)
Phase 2RecruitingHaitao Zhao, MD382026-10-012026-10-05

Showing 20 of 854. Sign in to see all of them.

Narrower conditions

Gallbladder Neoplasms (296)  ·  Bile Duct Neoplasms (250)  ·  Pancreatic Neoplasms (226)  ·  Cholangiocarcinoma (210)  ·  Stomach Neoplasms (144)  ·  Carcinoma, Hepatocellular (104)  ·  Colorectal Neoplasms (99)  ·  Liver Neoplasms (91)  ·  Esophageal Neoplasms (83)  ·  Neoplasms (73)  ·  Carcinoma, Non-Small-Cell Lung (72)  ·  Colonic Neoplasms (71)  ·  Breast Neoplasms (63)  ·  Endometrial Neoplasms (56)

Broader conditions

Neoplasms by Site (853)  ·  Digestive System Diseases (851)  ·  Digestive System Neoplasms (850)  ·  Biliary Tract Diseases (848)  ·  Neoplasms (781)  ·  Neoplasms by Histologic Type (360)  ·  Neoplasms, Glandular and Epithelial (344)  ·  Carcinoma (322)  ·  Adenocarcinoma (303)  ·  Gallbladder Diseases (297)  ·  Endocrine System Diseases (257)  ·  Endocrine Gland Neoplasms (256)  ·  Bile Duct Diseases (253)  ·  Gastrointestinal Diseases (232)

Interventions

Gemcitabine (164)  ·  Cisplatin (112)  ·  Capecitabine (69)  ·  Oxaliplatin (62)  ·  Fluorouracil (51)  ·  Leucovorin (40)  ·  durvalumab (40)  ·  pembrolizumab (39)  ·  Irinotecan (26)  ·  Bevacizumab (22)  ·  S 1 (combination) (22)  ·  130-nm albumin-bound paclitaxel (21)  ·  lenvatinib (18)  ·  Albumin-Bound Paclitaxel (17)  ·  Nivolumab (16)

Sponsors

National Cancer Institute (NCI) (39)  ·  AstraZeneca (19)  ·  Peking Union Medical College Hospital (16)  ·  Seoul National University Hospital (12)  ·  Samsung Medical Center (11)  ·  Kansai Hepatobiliary Oncology Group (10)  ·  Massachusetts General Hospital (9)  ·  Shanghai Zhongshan Hospital (9)  ·  Tianjin Medical University Cancer Institute and Hospital (9)  ·  Fudan University (8)  ·  Memorial Sloan Kettering Cancer Center (8)  ·  Asan Medical Center (7)  ·  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (7)  ·  Mayo Clinic (7)  ·  RenJi Hospital (7)

Countries

United States (323)  ·  China (208)  ·  South Korea (120)  ·  Japan (64)  ·  Germany (63)  ·  France (62)  ·  United Kingdom (57)  ·  Spain (56)  ·  Italy (45)  ·  Australia (43)  ·  Canada (43)  ·  Taiwan (42)  ·  Belgium (26)  ·  India (20)  ·  Denmark (18)

Top investigators

Michel Kahaleh, MD (7)  ·  Tim F Greten, M.D. (5)  ·  Hiroaki Nagano, MD, PhD (4)  ·  Tanios Bekaii-Saab (4)  ·  Vaibhav Sahai, MBBS, MS (4)  ·  Anthony El-Khoueiry (3)  ·  Do-Youn Oh, MD, PhD (3)  ·  Hong Jae Chon, MD. PhD (3)  ·  Joan B Gornals, PhD (3)  ·  Jonathan M Hernandez, M.D. (3)  ·  Julien Edeline, MD (3)

Results publications

PMID 20375404, PMID 37121331, PMID 33198671, PMID 37069476, PMID 38661512, PMID 24146220, PMID 25477010, PMID 26179201, PMID 28818953, PMID 29433850, PMID 29954008, PMID 29961772, PMID 30420614, PMID 30642373, PMID 30998813, PMID 32461347, PMID 32707155, PMID 33798493, PMID 34508767, PMID 34515993, PMID 34748675, PMID 37075781, PMID 37934000, PMID 38319896, PMID 40812353, PMID 41887529, PMID 42176183, PMID 10548868, PMID 10960937, PMID 11251976, PMID 11261621, PMID 11494194, PMID 11574279, PMID 12196376, PMID 12393999, PMID 12455783, PMID 12794246, PMID 12850683, PMID 14525967, PMID 15129896, PMID 15558814, PMID 15646530, PMID 16515225, PMID 16682732, PMID 16849762, PMID 16875082, PMID 17707751, PMID 18006327, PMID 18470481, PMID 18669454

NIH funding

2023 (17), 2015 (7), 2025 (5), P30CA015083 (5), 2018 (4), P30CA033572 (4), U10CA032102 (4), 2016 (3), 2017 (3), 2019 (3), N01CM00070 (3), N01CM62201 (3), P30CA068485 (3), U10CA180888 (3), N01CM17104 (2)